Navigation Links
New study finds neither HFCS nor table sugar increases liver fat under 'real world' conditions
Date:2/12/2013

SHREWSBURY, MA -- A study published today in the Journal of Applied Physiology, Nutrition, and Metabolism presented compelling data showing the consumption of both high fructose corn syrup (HFCS) and sucrose (table sugar) at levels consistent with average daily consumption do not increase liver fat in humans, a leading cause of non-alcoholic fatty liver disease (NAFLD). The findings also add to an already well-established body of science that high fructose corn syrup and table sugar are metabolically equivalent.

Increased fat levels in the liver and muscle tissue have also shown to contribute to insulin resistance, a key factor in the development of type 2 diabetes.

The study, conducted by James Rippe, MD, Founder and Director of the Rippe Lifestyle Institute and Professor of Biomedical Sciences at the University of Central Florida, examined sixty-four individuals who consumed low-fat milk sweetened with either HFCS or sucrose with the added sugar matching the 25th, 50th and 90th percentile population consumption levels of fructose for ten weeks.

The results showed fat content of the liver remained unchanged when the six HFCS and sucrose groups were averaged. Fat content in muscle tissue was also unchanged over the 10 weeks when the six HFCS and sucrose groups were averaged.

"The study's results are compelling because this is the first study of its kind to test the effects of HFCS and sucrose on liver fat levels in humans using real world conditions," said Dr. Rippe, who received a grant from the Corn Refiners Association (CRA) to conduct the study. "Previous studies that sought to find a link between caloric sweeteners and diseases such as type 2 diabetes and liver disease often subjected individuals to unrealistically high levels of fructose or had subjects consume fructose independent of glucose, which is just not how fructose is consumed in our daily diet. Using real world conditions, we find that HFCS and other caloric sweeteners do not appear to increase liver fat or contribute to insulin resistance."

The two largest sources of fructose in the human diet are sucrose (containing 50% fructose and 50% glucose) and HFCS which is present in the human diet in two forms: HFCS-55 (which consists of 55% fructose, 42% glucose and 3% other carbohydrates) and HFCS-42 (which consists of 42% fructose and 58% glucose).

"This study seems to confirm what physicians, registered dietitians and healthcare associations such as the American Medical Association have been saying for decades," said Dr. Mark Haub, Associate Professor in the Department of Nutrition at Kansas State University. "Not only is it safe to consume caloric sweeteners at recommended levels, it is important for consumers to understand that high fructose corn syrup and table sugar have the same amount of calories and studies like this indicate your body metabolizes them about the same."

For further information or to obtain a copy of this study, please visit www.nrcresearchpress.com/journal/apnm


'/>"/>

Contact: Carol Moreau
cmoreau@rippelifestyle.com
508-756-1228
Rippe Lifestyle Institute
Source:Eurekalert

Related biology news :

1. Study by UC Santa Barbara researchers suggests that bacteria communicate by touch
2. Law that regulates shark fishery is too liberal: UBC study
3. New study will help protect vulnerable birds from impacts of climate change
4. Study jointly led by UCSB researcher supports theory of extraterrestrial impact
5. BYU study: Using a gun in bear encounters doesnt make you safer
6. 15-year study: When it comes to creating wetlands, Mother Nature is in charge
7. Pycnogenol (French maritime pine bark extract) shown to improve menopause symptoms in new study
8. Crystal structure of archael chromatin clarified in new study
9. EU-funded study underlines importance of Congo Basin for global climate and biodiversity
10. University of Houston study shows BP oil spill hurt marshes, but recovery possible
11. Study demonstrates cells can acquire new functions through transcriptional regulatory network
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/22/2016)... Minn. , Nov. 22, 2016   MedNet ... supports the entire spectrum of clinical research, is pleased ... Medical LiveWire Healthcare and Life Sciences Awards ... award caps off an unprecedented year of recognition and ... trials for over 15 years. iMedNet ...
(Date:11/17/2016)... Nov. 17, 2016  AIC announces that it has just released a new white ... require high-performance scale-out plus high speed data transfer storage solutions. Photo - ... ... ... Setting up a high performance computing or ...
(Date:11/14/2016)... 14, 2016  xG Technology, Inc. ("xG" or the ... wireless communications for use in challenging operating environments, announced ... 2016. Management will hold a conference call to discuss ... Eastern Time (details below). Key Recent Accomplishments ... million binding agreement to acquire Vislink Communication Systems. The ...
Breaking Biology News(10 mins):
(Date:12/8/2016)... (PRWEB) , ... December 08, 2016 , ... ... the FrontPanel SDK that provide essential device-to-computer interconnect using USB or PCI Express, ... require FrontPanel support. The FOMD-ACV-A4 is a small, thin, SODIMM-style module that fits ...
(Date:12/8/2016)... , ... December 08, 2016 ... ... the commercial launch of flexible packaging for their exceptionally efficient human mesenchymal ... system extends RoosterBio’s portfolio of bioprocess media products engineered to radically streamline ...
(Date:12/8/2016)...  HedgePath Pharmaceuticals, Inc. (OTCQX: HPPI), a clinical ... to commercialize innovative therapeutics for patients with cancer, ... approved for trading on the OTCQX U.S. market. ... effective today, under the ticker symbol "HPPI." ... must meet high financial standards, follow best practice ...
(Date:12/7/2016)... Diego (PRWEB) , ... December 07, 2016 , ... ... data from its phase I/II dose escalation and expansion clinical trial for its ... in Vienna, Austria. The purpose of the trial was to determine the safety, ...
Breaking Biology Technology: